DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Phase of Trial: Phase II
Latest Information Update: 28 Aug 2019
Price : $35 *
At a glance
- Drugs Temozolomide (Primary) ; Varlilumab (Primary) ; Dendritic cells; Diphtheria-tetanus vaccine
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms DERIVe
- 21 Aug 2019 Status changed from recruiting to suspended.
- 23 Jul 2019 Status changed from not yet recruiting to recruiting.
- 11 Jul 2019 Planned initiation date changed from 1 Jun 2019 to 1 Aug 2019.